Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With ...
AbbVie GK, Eisai Co. and EA Pharma Co. have debuted the HUMIRA Pen, an auto-injector pen meant to help simplify self-injection. The product, which has a rounded pen-type body designed to help patients ...
FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.
TOKYO, Sept 27, 2021 - (JCN Newswire) - - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis ...
Gastroenterologists Are Using Biologic Agents, both Approved and Off-Label, More Aggressively for Patients with Active UC Than They Were One Year Ago, According to a Recent BioTrends Report BioTrends ...
SAN DIEGO – The VARSITY study results showed that clinical and endoscopic outcomes of Entyvio treatment were superior to those of Humira in moderately to severely active ulcerative colitis at 1 year, ...
Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative. Alberta, Canada has expanded ...
Medicare typically covers Humira through Part D when self-administered or Part B when administered by a doctor. As of 2025, Medicare beneficiaries won’t have to pay more than $2,000 ($2,100 in 2026) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback